Ensign Peak Advisors
SRPT icon

Ensign Peak Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Ensign Peak Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Sell
6,093
-150
-2% -$2.84K ﹤0.01% 1592
2026
Q1 		$136K Hold
6,243
– – ﹤0.01% 1487
2025
Q4 		$134K Sell
6,243
-9,650
-61% -$203K ﹤0.01% 1472
2025
Q3 		$306K Sell
15,893
-11,000
-41% -$196K ﹤0.01% 1565
2025
Q2 		$460K Hold
26,893
– – ﹤0.01% 1579
2025
Q1 		$1.72M Sell
26,893
-146,598
-84% -$15.4M ﹤0.01% 965
2024
Q4 		$21.1M Sell
173,491
-51,837
-23% -$6.35M 0.04% 313
2024
Q3 		$28.1M Hold
225,328
– – 0.05% 265
2024
Q2 		$35.6M Buy
225,328
+38,090
+20% +$4.89M 0.07% 211
2024
Q1 		$24.2M Sell
187,238
-7,192
-4% -$881K 0.04% 289
2023
Q4 		$18.7M Sell
194,430
-3,215
-2% -$308K 0.04% 306
2023
Q3 		$24M Sell
197,645
-480
-0.2% -$54.3K 0.05% 252
2023
Q2 		$22.7M Buy
198,125
+10,780
+6% +$1.39M 0.05% 278
2023
Q1 		$25.8M Buy
187,345
+39,985
+27% +$5.19M 0.06% 252
2022
Q4 		$19.1M Buy
147,360
+16,750
+13% +$1.94M 0.04% 301
2022
Q3 		$14.4M Buy
130,610
+110,080
+536% +$11.1M 0.04% 314
2022
Q2 		$1.54M Buy
20,530
+400
+2% +$29.4K ﹤0.01% 920
2022
Q1 		$1.57M Hold
20,130
– – ﹤0.01% 977
2021
Q4 		$1.81M Buy
+20,130
New +$1.72M ﹤0.01% 999
2021
Q1 		– Sell
-22,766
Closed -$3.88M – 1880
2020
Q4 		$3.88M Sell
22,766
-6,748
-23% -$1,000K 0.01% 708
2020
Q3 		$4.14M Buy
29,514
+22,901
+346% +$3.48M 0.01% 682
2020
Q2 		$1.06M Buy
6,613
+4,957
+299% +$675K ﹤0.01% 1260
2020
Q1 		$162K Sell
1,656
-1,147
-41% -$131K ﹤0.01% 1552
2019
Q4 		$362K Buy
+2,803
New +$283K ﹤0.01% 1559

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Ensign Peak Advisors's SRPT Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Sarepta Therapeutics (SRPT) stake by 2.4% in Q2 2026, selling an estimated $2.84K and leaving 6,093 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #1592.

Ensign Peak Advisors first reported a position in SRPT in Q4 2019 and has held it in 24 quarters since. The position peaked at $35.6M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Ensign Peak Advisors held 6,093 shares of Sarepta Therapeutics worth $109K as of Q2 2026.
  • Ensign Peak Advisors sold 150 Sarepta Therapeutics shares in Q2 2026, an estimated $2.84K.
  • Sarepta Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1592 holding.
  • Ensign Peak Advisors first reported a position in Sarepta Therapeutics in Q4 2019 and has held it in 24 quarters since.
  • Ensign Peak Advisors's Sarepta Therapeutics position peaked at $35.6M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.